Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress

Oslo, Norway, 27 August 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the abstract “A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma” will be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center. E-poster A pilot study of Engineered Adenovirus ONCOS-102 in

DanCann Pharma A/S publishes Q2-2021 report

COPENHAGEN, Denmark, 28 May 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby today releases its results for the period 1 April – 30 June 2021 (the “period”). The Q2-2021 report is available as an attached document to this press release and on www.dancann.com.Key figures Q2 2021 KDKK 01/04/21 01/04/20 30/06/20 01/01/21 30/06/21 01/01/20 30/06/20 30/06/21Net sales 0 0 0 0Operating -3,771 -1,237 -6,362 -1,499profit(EBIT)

BEWI ASA – Mandatory notification of trade and flagging announcement

Frøya Invest AS, a related party of CEO Christian Bekken, a PDMR of BEWI ASA, has on 27 August 2021, purchased a total of 6,779,661 shares from Verdane ETF III SPV K/S at NOK 29,50 per share. Following the transaction, Frøya Invest AS holds 95,112,813 shares. In addition, EBE Eiendom AS, also related to the Bekken family, owns 2,529,637 shares, and Christian Bekken holds 5,952 shares privately, summing up to a total holding of 97,648,402 shares, representing 62.35 per cent of the total outstanding shares in BEWI ASA. Christian Bekken also holds 250,000 options in BEWI ASA. Please see the

SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)

“Positive data of AP1189 in Covid-19 patients bodes well for the future. The hard work at the start of the year continued in the second quarter as SynAct Pharma made additional progress on its pipeline. The Covid-19 pandemic has certainly added complexity, but we have clear priorities, and our attractive project pipeline is progressing well. Our future is bright, and the second half of 2021 promises to be another busy period for us,” said SynAct Pharma’s CEO Jeppe Øvlesen.Summary of Half-Year 2021 interim report Second quarter (2021-04-01 – 2021-06-30) · Consolidated net sales

BioStock: Show of resilience from BiBBInstruments during Q2

Despite the challenges driven by the pandemic and some production issues during the first half of 2021, Swedish medtech BiBBInstruments has managed to keep to the scheduled clinical timelines for evaluating the world’s first CE-marked electric biopsy instrument - EndoDrill Model X. BioStock reached out to CEO Fredrik Lindblad for a comment.Read the full interview with Fredrik Lindblad at biostock.se: https://www.biostock.se/en/2021/08/show-of-resilience-from-bibbinstruments-during-q2/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se (

Omnicar Holding AB Q2 2021 report

Dear shareholders  Exactly one year ago, we launched the idea of our new mobile workshop concept and on 1 October 2020 our very first mobile service van rolled onto the streets - our Q2 report 2021 numbers reflects some of our accomplishments  Now, 12 months later, we are delighted to have reached the following key milestones: ·85% revenue growth in Q2 2021 compared to same periode last year ·The best customer satisfaction in the industry · Five service vans in the Greater Copenhagen area – number six is on its way · New CEO for Omnicar Holding and Omnicarservice

BioStock: Iconovo’s partner explores opportunities in Bangladesh

Together with ISR, Iconovo is developing an inhaled Covid-19 vaccine in ICOone and a nasal version in ICOone Nasal. ISR has now signed a MoU agreement with the CRO Bangladesh Clinical Trials for a clinical phase I study with the vaccine, as well as with UniMed UniHealth Pharmaceuticals for manufacturing and distribution in Bangladesh. However, these agreements are only declarations of intent, not binding agreements, but they are nevertheless good news for Iconovo as it means significant progress within the vaccine project.Read the full article at biostock.se: https://www.biostock.se/en/

Redwood Pharma AB (publ) Quarterly Report January – June 2021

NASDAQ FIRST NORTH GROWTH MARKET:REDW.ST, REDWOODPHARMA.COM Period 1 January–30 June 2021 · The company’s net revenue for the period totalled kSEK 0 (0). · Operating profits for the period totalled kSEK -10,916 (-8,026). · Earnings per share for the period were SEK -0.41 (-0.54). Period 1 April –30 June 2021 · The company’s net revenue for the period totalled kSEK 0 (0). · Operating profits for the period totalled kSEK -6,981 (-3,594). · Earnings per share for the period were SEK -0.34 (-0.24). Significant events during the period · Redwood Pharma

Interim Report 1 January to 30 June 2021

Financial Summary for the groupKSEK Q2 Q2 Q1-Q2 Q1-Q2 2021 2020 2021 2020Profit/loss before tax -11 458 -14 197 -20 069 -24 394Total assets 69 240 58 357 69 240 58 357Earnings per share before -0,19 -0,29 -0,34 -0,50and after dilution (SEK)Cash and cash equivalents 54 054 41 611 54 054 41 611as per period endEquity ratio as per 92,6% 89,3% 92,6% 89,3%period end Significant events during the second quarter of 2021 · World leading

BoMill publishes half-year report for second quarter and first six months 2021

BoMill AB (”BoMill” or the “Company”) hereby publishes the half-year report for the second quarter and the first six months of 2021. The half-year report is available as an attached file to this release and on BoMill’s website. Below is a summary of the report.CEO Andreas Jeppsson comments: “We are very motivated in the journey that lies ahead of us. With the knowledge that the entire market is in a need of modernized technology, the timing is right. I am excited about or ongoing development and our business strategy, delivering value to producers, grain handlers, the processing industry

Sedana Medical's Sedaconda study published in the Lancet

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the results of the company's pivotal study Sedaconda (SED001) have been published in the highly ranked scientific journal, the Lancet Respiratory Medicine."We are very pleased that the study is published in Lancet Respiratory Medicine. The results of the study, which is the largest in inhaled sedation, point to the efficacy and safety of isoflurane via AnaConDa as well as the benefits of the therapy, namely reduced need of opioids, increased spontaneous breathing and faster awakening. Overall, there are now strong reasons

Scandion Oncology receives German trial approval for PANTAX Ib study

Scandion Oncology A/S today announced that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study.The German medicines agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the German ethics committee have given approval, allowing Scandion Oncology to expand the PANTAX Ib study to Germany. “We are very pleased to receive this German approval as BfArM is highly regarded and known for having tough critera. The approval is important for the PANTAX Ib study, but it also opens the

SynAct Pharma: Interim Report January-June 2021 August 27, 2021

“Positive data of AP1189 in Covid-19 patients bodes well for the future. The hard work at the start of the year continued in the second quarter as SynAct Pharma made additional progress on its pipeline. The Covid-19 pandemic has certainly added complexity, but we have clear priorities, and our attractive project pipeline is progressing well. Our future is bright, and the second half of 2021 promises to be another busy period for us,” said SynAct Pharma’s CEO Jeppe Øvlesen.Summary of Half-Year 2021 interim report Second quarter (2021-04-01 – 2021-06-30) · Consolidated net sales

Lipum AB - interim report for the period January - June 2021

Press release: Umeå, 27 August, 2021. Lipum AB has published the interim report for period January to June 2021. Below is a brief summary, a complete report (only in Swedish) is available on the company's website .CEO Einar Pontén comments: “Lipum has reached a stage when we are preparing for clinical trials. Important intermediate goals have been achieved during the first half of the year. Toxicology- and safety studies are progressing according to plan as well as the upscaling of the production process of our drug candidate SOL-116”. Financial

BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents

The USD 15 million deal marks BICO’s sixth acquisition this year, and further strengthening the company’s status as a leader in Bio Convergence.BICO, the leading Bio Convergence company, has acquired all outstanding shares in Advanced BioMatrix Corp. (Advanced BioMatrix), an American company focusing on 3D research applications. The Advanced BioMatrix portfolio includes collagen bioinks, high purity extracellular matrix proteins, chemically modified proteins and polysaccharides, and other reagents and cell assays, sold to research institutions, and pharmaceutical and biotech companies. The

Zalaris awarded ‘Best Payroll & HR Solutions Provider – Sweden’ at Scandinavian Business Awards

Zalaris ASA, a leading provider of Outsourced Payroll and HR services, is happy to announce it has been awarded the Best Payroll & HR Solutions Provider – Sweden at the Scandinavian Business Awards by EU Business News.EU Business News is a quarterly online magazine and B2B platform designed to inform readers of the latest market developments across Europe and is produced by the larger publishing house AI Global Media. Circulated to 54,000 C-suite executives and decision makers across Europe and alongside their online publication, they host a series of annual award programmes dedicated to

Principal shareholders issue call options to senior executives in SyntheticMR

SyntheticMR AB (publ) (”SyntheticMR”) announced today that leading executives (CEO and Head of US region) agreed on the purchase of a total of 300 000 call options. The options are issued by SyntheticMR’s principal shareholders (Nortal Investments AB, managed by Staffan Persson), founder (Marcel Warntjes) and Chairman of the Board (Johan Sedihn), which means there is no dilution for other shareholders. Holders have the right to acquire one (1) share in SyntheticMR for each call option. The duration of the incentive program is almost 5 years and exercising the call options can take place

The Chinese premium chain City Shop to launch DUG in its stores

City Shop is one of Shanghai’s largest chain stores with a clear focus on premium products and a high level of service. From September, City Shop will offer its customers Veg of Lund’s plant-based drink DUG[®] on the shelves.City Shop was established in 1995 with the goal of offering a wide range of food with high quality and best service. Today, City Shop has 13 stores in Shanghai's central residential areas and two stores in Beijing. “The fact that Veg of Lund has an agreement with City Shop gives us access to and an opportunity to expose our brand to purchasing power and conscious

LeadDesk’s organic growth and acquisitions fire up an excellent start to the year

LeadDesk Ltd Unofficial Translation of Press Release 27/8/2021 at 9.05 am. In case the document differs from the original, the Finnish version prevails.LeadDesk Ltd Half Year Financial Statement 1/1–30/6/2021 Figures in parenthesis refer to the equivalent period in the previous year, unless otherwise stated.  (Unaudited)   January–June 2021 ·Revenue EUR 12,022 (6,211) thousand, growth 93.6% · Comparable revenue EUR 12,542* (10,917**) thousand, growth 14.9% · Annual recurring revenue EUR 19 059 (9,704) thousand, growth 96,4% · EBITDA EUR 1,868 (623) thousand, 15.5 (

DBP International AB: The EC/CA submission for SI-053 has been sent to the Netherlands

Double Bond Pharmaceutical International AB (publ) ("DBP") takes another step towards the start of the phase 1 multinational multicentral clinical trial of its front-line product SI-053 in patients with glioblastoma - the Ethical Committee/Competent Authority submissions for SI-053 in The Netherlands has also been sent.As previously was reported the Clinical Trial Application (CTA) was sent and the CTA concerned 3 sites in Germany. With the current submission in the Netherlands DBP adds additionally a site for the trial. The process

AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses

Stockholm, Sweden, August 27, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the Medical Products Agency to be able to give additional doses of ACD856 in the clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested.Data from the SAD study establish that ACD856, the lead candidate drug

Cinclus Pharma Appoints Maria Engström as Chief Financial Officer

Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for gastroesophageal reflux disease (“GERD”), today announced the appointment of Maria Engström as Chief Financial Officer (CFO).  Maria has extensive experience in the pharmaceutical industry and most recently from Sedana Medical where she was CFO from 2017 to early 2021.Maria Engström assumed the position already in August 2021.   ” The company are delighted in having recruited Maria Engström to Cinclus Pharma” said Christer Ahlberg, CEO. "Maria

Eltel signs 5G agreement in Norway worth 12-16 million euros

Eltel Norway has signed a project agreement with Telenor to upgrade its telecommunications network with 5G technology. The agreement is worth about 12-16 million euros.Through the project, which runs during 2022, Eltel is strengthening its leading position in the Norwegian market regarding the expansion and modernisation of telecommunications networks through 5G. Further information:Elin Otter, Director, Communications and Investor RelationsPhone: +46 72 595 4692, elin.otter@eltelnetworks.com About EltelEltel is a leading Nordic field service provider for communication and power

There are no items matching the current filter
There are no more items matching the current filter
Back to top